TABLE 3:

Univariable and Multivariable Predictors of Vedolizumab Loss of Response

Variable	Univariable HR (95% CI)	Multivariable HR (95% CI)
All IBD patients
IBD type (UC vs CD)	1.54 (1.04–2.28)
Disease duration	0.97 (0.95–0.99)	0.97 (0.95–0.99)
Prior hospitalization	0.84 (0.66–1.06)
Baseline CRP	1.01 (0.99–1.02)
LOR with last biologic	1.94 (1.26–2.98)	1.93 (1.25–2.97)
PNR with last biologic	0.60 (0.36–0.97)
Concomitant steroids	1.49 (1.01–2.21)
Crohn’s disease
BMI	0.96 (0.91–1.02)
Disease duration	0.98 (0.95–1.00)	0.95 (0.92–0.99)
Baseline CRP	1.01 (1.01–1.02)	1.01 (1.01–1.02)
Baseline albumin	0.69 (0.41–1.15)
LOR with last biologic	1.92 (1.09–3.41)	2.55 (1.31–4.96)
PNR with last biologic	0.57 (0.30–1.10)
Ulcerative colitis
TNF-antagonist failure	1.64 (0.90–2.99)
LOR with last biologic	1.93 (0.99–3.77)
Concomitant steroids	1.64 (0.89–3.02)

Variables selected based on univariable analyses (P < 0.20) and backward model selection approach used to derive final multivariable model (P < 0.05).

BMI, Body mass index; CD, Crohn’s disease; CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; IBD, inflammatory bowel disease; LOR, loss of response; PNR, primary nonresponse; UC, ulcerative colitis.